Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 457 - 464 of 12029 results

Telephone and Texting Compliance News: Litigation Update — A Win for TCPA Compliance and the Lead Generation Industry
November 27, 2024| Article| Viewpoint

GOP Election Sweep Threatens Niche College Tax Break
November 27, 2024| News

Energy & Sustainability Washington Update — December 2024
November 26, 2024| Article| Viewpoint

Nebraska’s Consumer Privacy Law Takes Effect Soon and Targets Businesses Selling Personal Data
November 26, 2024| Blog| Viewpoint

Massachusetts Supreme Judicial Court Upholds Trustee’s Adjustment from Principal to Income
November 26, 2024| Blog| Viewpoint

Mintz on Air - Predictions and Practical Policies
November 25, 2024| Podcast| Viewpoint

Legal Shifts Post-Election – What Employers Need to Know
November 25, 2024| Article| Viewpoint

PBM Policy and Legislative Update — Fall 2024
November 22, 2024| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
